| The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases |
648 |
| Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases |
480 |
| AASLD guidelines for the treatment of hepatocellular carcinoma |
448 |
| Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance |
397 |
| Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease |
213 |
| RNA N6-methyladenosine methyltransferase-like 3 promotes liver cancer progression through YTHDF2-dependent posttranscriptional silencing of SOCS2 |
174 |
| Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis |
132 |
| A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis |
101 |
| Estimating Prevalence of Hepatitis C Virus Infection in the United States, 2013-2016 |
86 |
| The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial |
74 |
| Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis |
67 |
| Assessment of biopsy-proven liver fibrosis by two-dimensional shear wave elastography: An individual patient data-based meta-analysis |
66 |
| Sex Differences in Nonalcoholic Fatty Liver Disease: State of the Art and Identification of Research Gaps |
65 |
| Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases |
60 |
| Hepatocellular Carcinoma Is Associated With Gut Microbiota Profile and Inflammation in Nonalcoholic Fatty Liver Disease |
58 |
| Altered amino acid concentrations in NAFLD: Impact of obesity and insulin resistance |
55 |
| 17-Beta Hydroxysteroid Dehydrogenase 13 Is a Hepatic Retinol Dehydrogenase Associated With Histological Features of Nonalcoholic Fatty Liver Disease |
55 |
| A Large-scale, multicenter serum metabolite biomarker identification study for the early detection of hepatocellular carcinoma |
55 |
| Intestine farnesoid X receptor agonist and the gut microbiota activate G-protein bile acid receptor-1 signaling to improve metabolism |
52 |
| Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis |
51 |
| Hepatoma cell-secreted exosomal microRNA-103 increases vascular permeability and promotes metastasis by targeting junction proteins |
50 |
| Landscape of immune microenvironment in hepatocellular carcinoma and its additional impact on histological and molecular classification |
49 |
| Recent developments of c-Met as a therapeutic target in hepatocellular carcinoma |
48 |
| cHCC-CCA: Consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentation |
47 |
| Endoplasmic Reticulum Stress Causes Liver Cancer Cells to Release Exosomal miR-23a-3p and Up-regulate Programmed Death Ligand 1 Expression in Macrophages |
46 |
| Unexpected Rapid Increase in the Burden of NAFLD in China From 2008 to 2018: A Systematic Review and Meta-Analysis |
45 |
| Neutrophil extracellular traps promote inflammation and development of hepatocellular carcinoma in nonalcoholic steatohepatitis |
44 |
| Imaging for the diagnosis of hepatocellular carcinoma: A systematic review and meta-analysis |
44 |
| Circular RNA MAT2B Promotes Glycolysis and Malignancy of Hepatocellular Carcinoma Through the miR-338-3p/PKM2 Axis Under Hypoxic Stress |
41 |
| Human CD96 Correlates to Natural Killer Cell Exhaustion and Predicts the Prognosis of Human Hepatocellular Carcinoma |
41 |
| Mouse Models of Nonalcoholic Steatohepatitis: Toward Optimization of Their Relevance to Human Nonalcoholic Steatohepatitis |
40 |
| The short-term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with direct-acting antivirals: An ERCHIVES study |
39 |
| Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection |
38 |
| Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B |
37 |
| Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death: A 20 year-community study |
37 |
| A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis |
37 |
| Changing Trends in Etiology-Based and Ethnicity-Based Annual Mortality Rates of Cirrhosis and Hepatocellular Carcinoma in the United States |
36 |
| Modulation of Insulin Resistance in Nonalcoholic Fatty Liver Disease |
35 |
| The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids |
35 |
| The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials |
35 |
| NACSELD acute-on-chronic liver failure (NACSELD-ACLF) score predicts 30-day survival in hospitalized patients with cirrhosis |
34 |
| Intrahepatic Cholangiocarcinoma: Continuing Challenges and Translational Advances |
34 |
| Taurine up-regulated gene 1 functions as a master regulator to coordinate glycolysis and metastasis in hepatocellular carcinoma |
34 |
| Long noncoding RNA TSLNC8 is a tumor suppressor that inactivates the interleukin-6/STAT3 signaling pathway |
34 |
| The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis |
33 |
| Exosome miR-335 as a novel therapeutic strategy in hepatocellular carcinoma |
33 |
| Interaction between alcohol consumption and metabolic syndrome in predicting severe liver disease in the general population |
33 |
| Modulation of the intestinal bile acid/farnesoid X receptor/fibroblast growth factor 15 axis improves alcoholic liver disease in mice |
33 |
| The high burden of alcoholic cirrhosis in privately insured persons in the United States |
33 |
| Institutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 000-patient 15-year experience |
31 |
